GenePlanet
A Slovenian healthtech company operating across clinical, preventive and research genomics.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Inforcer, Atomic One, GenePlanet — $50M, €5.6M and strategic capital for vertical AI — Daily News July 31, 2026
Listen to the episodeAbout GenePlanet
GenePlanet develops and distributes clinical and preventive genetic tests and end-to-end next-generation sequencing services, working through its own laboratories and healthcare partners in more than fifty company-reported markets. The portfolio spans non-invasive prenatal screening, oncology and rare-disease panels, and sequencing services for laboratories and research centres. Following BlackPeak Capital’s investment the company completed four acquisitions, adding laboratories, licences, technology and geographic reach. In July 2026 Lauxera Capital Partners joined as a strategic investor while BlackPeak took a partial exit and remained a shareholder; the amount and valuation were not disclosed. The stated aim is to expand oncology and rare-disease testing and to enter Western European and US markets.
The Story
Founded in Ljubljana in 2008 by Marko Bitenc.
How GenePlanet works
Business Model
A B2B, B2C and B2B2C platform for genetic testing, laboratory services and sequencing.
Revenue Model
Sales of tests and laboratory services and agreements with healthcare partners; commercial terms have not been disclosed.
Products & Services
Key Products
- Clinical genetic tests
- Preventive genetic tests
- Next-generation sequencing services
- NIPT
- Oncology and rare-disease panels
Core Use Cases
- Clinical genetic testing
- Preventive genetic testing
- Prenatal screening
- Sequencing for labs and research
- Oncology panels
- Rare disease panels
Market & Clients
Key Customers
Consumers, physicians, laboratories and healthcare providers buying genetic tests and sequencing services.
Geographic Presence
How GenePlanet competes
Competitive Advantages
- A company-reported presence in more than fifty markets
- A pan-European laboratory platform
- A proprietary testing portfolio
How GenePlanet grows
Growth Strategy
Expand oncology and rare-disease testing, enter Western European and US markets and continue targeted acquisitions.
Distribution Model
Direct sales, e-commerce, healthcare partners, laboratories and local distributors.
Moat (Defensibility)
Laboratories, certifications, genomic data, intellectual property, healthcare relationships and regulated market access.
Regulatory Context
Genetic tests and diagnostic services are governed by medical-device, laboratory, informed-consent, privacy and reimbursement requirements.
Key Risks
- Clinical validation
- Regulation and reimbursement
- Genetic-data privacy
- Acquisition integration
- Interpretation and communication of results
Strategic Insights
- Specialist capital may accelerate regulation, reimbursement and commercialisation in healthcare markets.
- Acquisitions have added laboratories, licences, technology and geographic reach.
Funding & Investors
Funding Rounds
- 2026 - Strategic investment: Undisclosed
Lead: Lauxera Capital Partners
Key Investors
Founding Team
Founders
Key Metrics
Lessons from GenePlanet
- In healthtech, regulated distribution can matter as much as the scientific product.
- A vertical investor may contribute operating expertise in addition to capital.
Similar Startups
DocPlanner
Europe's leading medical booking platform: 2M+ healthcare professionals, 22M appointments/month, $1B valuation across 13 European and LATAM countries.
Read AnalysisDoctolib
Healthcare booking platform connecting patients with doctors and dentists, handling appointments and digital health services.
Read AnalysisAlan
Digital health insurance platform offering transparent, affordable health coverage for individuals and SMEs.
Read AnalysisSources
- Lauxera joins GenePlanet as a strategic investor to support the next phase of global growth — GenePlanet
- Lauxera Capital Partners Invests in GenePlanet to Drive Global Diagnostics Expansion — Lauxera Capital Partners
- Lauxera invests in Slovenia-founded GenePlanet — SeeNews
- Slovenia’s GenePlanet secures strategic investment from Lauxera — EU-Startups